Antibodies against a peptide epitope of apolipoprotein B

Details Antibodies against a peptide epitope of apolipoprotein B Antibodies against a peptide epitope of apolipoprotein B

2009-02-27

2011-10-04

Bunner, Bridget E (Department: 1647)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S139100, C514S021400, C530S326000, C530S387100, C530S387900

Reexamination Certificate

active

08029786

ABSTRACT:
The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of the antibodies.

REFERENCES:
patent: 4970144 (1990-11-01), Fareed et al.
patent: 5408038 (1995-04-01), Smith et al.
patent: 5827516 (1998-10-01), Urban et al.
patent: 5861276 (1999-01-01), Kwak et al.
patent: 5972890 (1999-10-01), Lees et al.
patent: 2004/0002111 (2004-01-01), Hansson et al.
patent: 0911344 (1999-04-01), None
patent: 1186299 (2002-03-01), None
patent: 1394177 (2004-03-01), None
patent: 93/18067 (1993-09-01), None
patent: 94/00592 (1994-01-01), None
patent: 97/43311 (1997-11-01), None
patent: 98/13385 (1998-04-01), None
patent: 98/42751 (1998-10-01), None
patent: 98/56938 (1998-12-01), None
patent: 9908109 (1999-02-01), None
patent: 9918986 (1999-04-01), None
patent: 9946598 (1999-09-01), None
patent: 00/02920 (2000-01-01), None
patent: 01/32070 (2001-05-01), None
patent: 0157274 (2001-08-01), None
patent: 01/64008 (2001-09-01), None
patent: 01/68119 (2001-09-01), None
patent: 02/06314 (2002-01-01), None
patent: 0242426 (2002-05-01), None
patent: 0248388 (2002-06-01), None
patent: 03/007689 (2003-01-01), None
Herzyk et al. Biochim Biophys Acta 922: 145-154, 1987.
Chehin et al. Early stages of LDL oxidation: apolipoprotein B structural changes monitored by infrared spectroscopy. J Lipid Res 42: 778-782, 2001.
Skolnick et al., “From genes to protein structure and function: novel applications of computational approaches in the genomic era”; Trends in Biotech, Jan. 2000, vol. 18.; pp. 34-39.
Peer Bork; “Powers and Pitfalls in sequence Analysis: The 70% Hurdle”; Genome Research; Cold Spring Harbor Laboratory Press, 2000, pp. 398-400.
Doerks et al., “Protein annotation: detective work for function prediction”; Trends in Genetics; Jun. 1998, vol. 14, No. 6, pp. 248-250.
Smith et al., “The challenges of genome sequence annotation of “The devil is in the details””; Nature Biotechnology; Nov. 1997, vol. 15, pp. 1222-1223.
George et al., “Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis”; Atherosclerosis; 1998, vol. 138; pp. 147-152.
Palinski et al., “Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis”; Proc. Natl. Acad. Sci. USA, Jan. 1995, vol. 92, pp. 821-825.
Fredrikson et al., “Identivication of Immune Responses Against Aldehyde-Modified Peptide Sequences in ApoB Associated With Cardiovascular Disease”; Arterioscler Thromb Vasc. Biol.; May 2003; pp. 872-878.
Fredrikson et al., “Inhibition of Atherosclerosis in ApoE-Null Mice by Immunization with ApoB-100 Peptide Sequences”; Arterioscler Thromb Vasc. Biol.; May 2003; pp. 879-884.
Fredrikson et al., “Atheroproctective Immunization with MDA-modified apo B-100 peptide sequences is associated with activation of Th2 specific antibody expression”; Autoimmunity, Mar. 2005; vol. 38, No. 2; pp. 171-179.
Goldberg et al., “The NH2-terminal Region of Apolipoprotein B is Sufficient for Lipoprotein Association with Glycosaminoglycans”; The Journal of Biological Chemistry; Dec. 1998; vol. 273, No. 52; pp. 32355-35361.
Goncalves et al., “Humoral Immune Response Against Defined Oxidized Low-Density Lipoprotein antigens Reflects Structure and Disease Activity of Carotid Plaques”; Arterioscler Thromb Vasc. Biol.; 2005, pp. 1250-1255.
Ameli et al., “Effect of Immunization With Homologous LDK and oxidized LDL on Early Atherosclerosis in Hypercholesterolemic Rabbits”; Arteriosclerosis, Thrombosis, and Vascular Biology; 1996; pp. 1074-1079.
Steven E. Brenner; “Errors in genome annotation”; Trends in Genetics; Apr. 1999, vol. 15, No. 4, pp. 132-133.
Bork et al., “Go hunting in sequence databases but watch out for the traps”; Trends in Genetics; Oct. 1996, vol. 12, No. 10, pp. 425-427.
James A. Wells; “Additivity of Mutational Effects in Proteins”; Perspectives in Biochemistry; Sep. 1990, vol. 29, No. 37, pp. 8509-8517.
Ngo et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox”; The Protein Folding Problem and Tertiary Structure Prediction; 1994. pp. 492-495.
Hammer et al., “Generation, Characterization, and Histochemical Application of Monoclonal Antibodies Selectively Recognizing Oxidatively Modified ApoB-Containing Serum Lipoproteins”; Atreriosclerosis, Thrombosis, and Vascular Biology; 1995, pp. 704-713.
Ballow et al., “Immunomodulation and Immunotherapy”; JAMA, Dec. 1997, vol. 278, No. 22, pp. 2008-2017.
Gordon P. Moore; “Genetically Engineered Antibodies”; Clincal Chemistry, 1989, vol. 35, No. 9, pp. 1849-1853.
Fredrikson et al., “Treatment with apo B peptide vaccines inhibits atherosclerosis in human apo B-100 transgenic mice without inducing an increase in peptide-specific antibodies”; Journal of Internal Medicine; 2008, pp. 563-570.
Nilsson et al., “Immunization With Homologous Oxidized Low Density Lopoprotein Reduces Neointimal Formation After Balloon Injury in Hypercholesterolemic Rabbits”; JACC, vol. 30, No. 7, Dec. 1997, pp. 1886-1891.
Freigang et al., “Immunization of LDL Receptor-Deficient Mice With Homologous Malondialdehyde-Mofidied adn Native LDL Reduces Progression of Atherosclerosis by Mechanisms Other Than Induction of High Titers of Antibodies to Oxidative Neoepitopes”; Arterioscler Thromb Vasc. Biol., Jul. 1998, pp. 1972-1982.
Zhou et al., “LDL Immunization Induces T-Cell-Dependent Antibody Formation and Protection Against Atherosclerosis”; 2001, pp. 108-114.
Palinski, Wulf et al. “Antisera and Monoclonal Antibodies Specific for Epitopes Generated during Oxidative Modification of Low Density Lipoprotein” Arteriosclerosis vol. 10, No. 3; pp. 325-335; May/Jun. 1990.
Rosenfeld, Michael E. “Distribution of Oxidation Specific Lipid-Protein Adducts and Apolipoprotein B in Atherosclerotic Lesions of Varying Severity from WHHL Rabbits” Arteriosclerosis vol. 10, No. 3; pp. 326-349; May/Jun. 1990.
Lefvert, A.K. “Heterogeneity of autoantibodies against cardiolipin and oxidatively modified LDLs revealed by human monoclonal antibodies” Journal of Internal Medicine 2000: 247; pp. 285-390.
Dunning, Allison et al. “Association between epitopes detected by monclonal antibody BIP and the Xbal polymorphism of Apolipoprotein B” Clinical Genetics 1988: 33: pp. 181-188.
Chen, San-Hwan et al. “Apolipoprotein B-48 Is the Product of a Messenger RNA with an Organ-Specific In-Frame Stop Codon.” Science, vol. 238 1987; pp. 363-366.
Young, Stephen G. et al. “Definition of a nonlinear conformational epitope for the apolipoprotein B-100-specific monoclonal antibody, MB47.” Journal of Lipid Research; vol. 35; pp. 399-407; 1994.
Fredrikson, Gunilla Nordin et al. “Immunzation of atherosclerosis in apo E null mice by immunization with native and MDA-modified apo B peptide sequences” Journal of the American College of Cardiology, Elsevier, New York, NY, US; vol. 39, No. 5; Supplement A; p. 240A; Mar. 2002.
Knott, T.C. et al. “RecName:Full=Apolipoprotein B-100; Short=Apo B-100; Contains: RecName: Full=Apolipoprotein B-48; Short=Apo B-48; Flags: Precursor” UNIPROT, Jan. 11, 2001.
English translation of the Official Rejection issued in connection with corresponding JP Application No. 2008-015545, drafting date Apr. 22, 2010.
English translation of the Official Rejection issued in connection with corresponding JP Application No. 2002-578993, drafting date Apr. 22, 2010.
US Office Action issued in connection with corresponding U.S. Appl. No. 12/394,827, maile

Affiliated with

Also associated with

Rating

Antibodies against a peptide epitope of apolipoprotein B does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies against a peptide epitope of apolipoprotein B, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies against a peptide epitope of apolipoprotein B will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4273690